

**Supplementary Table 2.** Incidence of GIB in Propensity Score-Matched Patients Treated with NOACs and Warfarin Group in the Overall Cohort (n = 79,528)

Variable	All GIB (n = 2,570)			Upper GIB (n = 764)			Lower GIB (n = 322)			GIB with transfusion (n = 1,446)		
	Patients	GIB	Event rate (%)	Patients	GIB	Event rate (%)	Patients	GIB	Event rate (%)	Patients	GIB	Event rate (%)
Warfarin	39,764	1,440	3.62	39,764	415	1.04	39,764	188	0.42	39,764	862	2.17
NOACs	39,764	1,130	2.84	39,764	349	0.88	39,764	154	0.39	39,764	584	1.47
Apixaban	8,772	223	2.54	8,772	74	0.84	8,772	30	0.34	8,772	110	1.25
Dabigatran	5,857	178	3.04	5,857	50	0.85	5,857	32	0.55	5,857	77	1.31
Rivaroxaban	25,135	729	2.90	25,135	225	0.90	25,135	92	0.37	25,135	397	1.58
Warfarin without aspirin	37,320	1,350	3.60	37,320	394	1.06	37,320	152	0.41	37,320	808	2.17
Warfarin plus aspirin	2,444	90	3.70	2,444	21	0.86	2,444	16	0.65	2,444	54	2.21
NOACs without aspirin	37,473	1,044	2.80	37,473	322	0.86	37,473	144	0.38	37,473	543	1.45
NOACs plus aspirin	2,291	86	3.80	2,291	27	1.18	2,291	10	0.44	2,291	41	1.79
Warfarin without antiplatelet <sup>a</sup>	36,700	1,326	3.60	36,700	389	1.06	36,700	150	0.41	36,700	792	2.16
Warfarin plus antiplatelet <sup>a</sup>	3,064	114	3.70	3,064	26	0.85	3,064	18	0.59	3,064	70	2.28
NOACs without antiplatelet <sup>a</sup>	36,832	1,022	2.80	36,832	314	0.85	36,832	140	0.38	36,832	532	1.44
NOACs plus antiplatelet <sup>a</sup>	2,932	108	3.70	2,932	35	1.19	2,932	14	0.48	2,932	52	1.77
Warfarin without PPI	17,704	667	3.80	17,704	198	1.12	17,704	75	0.42	17,704	405	2.29
Warfarin plus PPI	22,060	773	3.50	22,060	217	0.98	22,060	93	0.42	22,060	457	2.07
NOACs without PPI	17,965	527	2.90	17,965	162	0.90	17,965	78	0.43	17,965	287	1.60
NOACs plus PPI	21,799	603	2.80	21,799	187	0.86	21,799	76	0.35	21,799	297	1.36

<sup>a</sup>Antiplatelets include clopidogrel, ticagrelor and prasugrel.  
GIB, gastrointestinal bleeding; NOACs, non-vitamin K antagonist oral anticoagulants; PPI, proton pump inhibitor.